Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular In... ( STOCKHOLM October 2 /- Athera Bio...)

HOME >> MEDICINE >> TECHNOLOGY

Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation

Date:10/2/2008

STOCKHOLM, October 2 /PRNewswire/ -- Athera Biotechnologies AB and Dyax Corp. (NASDAQ:DYAX) announced today that they have entered into a collaboration to discover and to develop therapeutic products for the prevention or treatment of cardiovascular inflammatory diseases.

The collaboration follows the recent publication of work by Athera scientific founders, Professors Frostegard and de Faire of the Karolinska Institutet. The research links naturally occurring antibodies against phosphorylcholine (PC) to atherosclerosis, and correlates low antibody levels with an increased risk of developing cardiovascular disease. Atherosclerosis is a chronic inflammatory disease in which the walls of the blood vessels are thickened and become less elastic.

During the discovery phase of the collaboration, Dyax will utilize its proprietary antibody libraries to generate fully human monoclonal antibodies. Athera will provide reagents, assays, and in vivo animal models for use in selecting a clinical product candidate. Upon successful completion of the discovery work, Athera and Dyax will have the option to advance the antibody lead(s) into clinical development under the terms of a global co-development and commercialization agreement.

"We are very pleased to be working with Athera," commented Clive Wood, EVP, Discovery Research and CSO of Dyax Corp. "Through their innovative research from the Karolinska Institutet, we believe Athera has identified an exciting potential opportunity for therapeutic antibody treatment of cardiovascular inflammation."

"The strength of Dyax's phage display technology, screening capabilities and expertise in drug discovery make them an excellent partner to advance our cardiovascular research program,"
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
2. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results

Post Your Comments:

Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular In...( STOCKHOLM October 2 /- Athera Bio...),Health